ClinicalTrials.gg
CompletedNCT07025811Updated Jul 27, 2026

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

A Phase 4 interventional study of Vevye® and Xiidra® in Dry Eye Disease, sponsored by Hoffmann-La Roche. Completed at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Enrollment
2nd of 41
378 · median 51
Started
2025
with 1 other
Phase 4
23 of 45
3 open now
Registered
40th of 45
by date

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 2nd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2025, is one of 23 in phase 4, and was the 40th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).

Read the detailed description

This study aims to characterize longitudinal changes in signs, symptoms, molecular, and imaging markers of the ocular surface to investigate pathological mechanisms and biomarkers (BMs) of DED after treatment with either of two commercially approved therapeutics (Vevye® [cyclosporine ophthalmic solution], Xiidra® [liftegrast ophthalmic solution]).

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Inclusion Criteria for Participants with DED:

  • The participant reported dry eye-related ocular symptoms for at least 6 months before the screening visit
  • The participant must have either used lubricant eye drops regularly OR had the desire to use lubricant eye drops in the past 3 months
  • Participant must be classified as having moderate/severe DED
  • The participant is deemed by the physician to require a prescription medication for DED (e.g., cyclosporin A or lifitegrast)

B. Inclusion Criteria for Healthy Volunteers:

- The participant does not have overt clinical signs of DED in either eye

Exclusion criteria

Exclusion Criteria:

  • Intraocular pressure (IOP) >21.00 millimeters of mercury (mmHg) in either eye
  • Acute allergic conjunctivitis in either eye within 3 months prior to screening
  • Use of contact lenses within 30 days prior to screening
  • Punctal plugs within 3 months prior to screening or any history of punctal cauterization or occlusion by an approach different from punctal plugs
  • Use of ocular anti-inflammatory agents or ocular agents within 3 months prior to screening
  • Any intraocular injections (e.g., intravitreal [IVT] anti-vascular endothelial growth factor [VEGF]) within 3 months prior to screening, or such injections planned for within the study period
  • Any intraocular immunosuppressive implants within 12 months prior to screening
  • Any history of isotretinoin use within 12 months prior to screening
  • Uncontrolled ocular or systemic disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
378 participants (actual)

Study arms

  • Experimental
    Vevye®

    Participants with evaporative dry eye (EDE), aqueous deficient dry eye (ADDE) and mixed dry eye will receive Vevye®, 1 milligrams per milliliter (mg/mL) as one drop into the affected eye(s), twice daily (BID) via topical ocular instillation for 12 weeks.

    Drug: Vevye®

  • Experimental
    Xiidra®

    Participants with EDE, ADDE, and mixed dry eye will receive Xiidra®, 50 mg/mL as one drop into the affected eye(s), BID via topical ocular instillation for 12 weeks.

    Drug: Xiidra®

  • No intervention
    Healthy Cohort

    Healthy volunteers will be enrolled as a control group and will not receive any treatment.

Interventions

  • Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.

    Also known as: Cyclosporine Ophthalmic Solution

  • Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.

    Also known as: Lifitegrast Ophthalmic Solution

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Corneal Staining as Measured by Sodium Fluorescein

    Time frame: Up to Week 12

07

Study locations

8 sites
  • Eye Research Foundation
    Newport Beach, California 92663, United States
  • Butchertown Clinical Trials
    Louisville, Kentucky 40206, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
  • Oculus Research
    Garner, North Carolina 27529, United States
  • CORE Inc.
    Shelby, North Carolina 28150, United States
  • Advancing Vision Research, LLC
    Goodlettsville, Tennessee 37072, United States
  • Total Eyecare, P.A.
    Memphis, Tennessee 38119, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jul 2026, 12 months.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 12 months is above that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jun 18, 2025
StartActual
Jul 9, 2025
Primary completionActual
Jul 16, 2026
CompletionActual
Jul 16, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07025811
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Jul 9, 2025
Primary completion
Jul 16, 2026
Completion
Jul 16, 2026
Last update
Jul 27, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclosporine · Lifitegrast

Start the discussion